BioAtla, Inc.
OOTC:BCAB1.23
USD
-0.13
(-9.29%)
CIK
1826892
ISIN
US09077B2034
CUSIP
09077B203
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jay M. Short
- Full Time Employees
- 41
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- San Diego United States
- CIK
- 0001826892
- Website
- bioatla.com
- Similar Companies
- Business
- BioAtla, Inc. is a clinical-stage biopharmaceutical company that develops novel, reversibly active monoclonal antibody and antibody-drug conjugate therapeutics for the treatment of solid tumor cancers. Founded in 2007 and headquartered in San Diego, California, the company utilizes its proprietary Conditionally Active Biologics (CAB) protein discovery and engineering platform to generate therapeutics that selectively bind and activate in the acidic microenvironment characteristic of diseased tumor tissue while remaining largely inactive in normal systemic circulation, thereby expanding the therapeutic window and mitigating target-mediated off-tumor toxicities. The company's product and candidate portfolio includes mecbotamab vedotin (BA3011), a CAB antibody-drug conjugate (ADC) targeting AXL in Phase 2 clinical evaluation for patients with soft tissue and bone sarcomas, non-small cell lung cancer (NSCLC), and ovarian cancer; ozuriftamab vedotin (BA3021), a CAB ADC targeting receptor tyrosine kinase-like orphan receptor 2 (ROR2) in Phase 2 clinical evaluation for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), NSCLC, and melanoma; BA3071, a conditionally active anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody evaluated as a monotherapy and in combination with PD-1 inhibitors for advanced solid tumors; BA3182, a dual-targeted CAB EpCAM x CD3 T-cell engaging bispecific antibody designed for the treatment of EpCAM-positive advanced adenocarcinomas including colorectal, lung, breast, and prostate cancers; and BA3361, a preclinical CAB ADC targeting Nectin-4 for multiple solid tumor indications. BioAtla operates research, development, and administrative facilities in the United States and conducts clinical trial operations across North America, Europe, and the Asia-Pacific region, maintaining strategic relationships with global contract development and manufacturing organizations as well as commercial biopharmaceutical partners. In recent developments, BioAtla implemented corporate restructuring and pipeline reprioritization initiatives to optimize operating expenses and extend cash runway, concentrating clinical resources on key Phase 2 combination and monotherapy cohorts for mecbotamab vedotin and ozuriftamab vedotin. Additionally, the company transitioned the public trading of its common stock to the OTCQX Best Market under the ticker symbol BCAB following its transfer from the Nasdaq Global Market, while advancing business development discussions for strategic licensing and co-development collaborations across its CAB ADC and bispecific T-cell engager assets.